Researchers at Radboud University Medical Centre Nijmegen in the Netherlands prospectively followed three patients with melanoma who developed vitiligo after receiving immunotherapy with autologous monocyte-derived dendritic cells loaded with HLA-A2.1 compatible tumor antigens gp100 and tyrosinase. Immunohistochemical analysis of the vitiligo lesions in all three patients showed perilesional infiltration of CD8-positive T-cells specific for one or more gp100 and tyrosinase HLA-A2.1 epitopes. These infiltrating lymphocytes were also found in the tumor lesions and produced interferon-gamma and IL-2 when stimulated with gp100- or tyrosinase-expressing target cells. These results suggest that vitiligo is a marker of immunity against melanoma (Jacobs, J.F. et al. Cancer Immunol Immunother 2009, 58[1]: 145).